ࡱ> FmDNgϔ@ݱsJFIFddC      , }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz?S((((((((((((((((((((((((((((4fњ3Fh4fњ3Fh4fњ3Fh4fKEQEQE2(((Z((()W:((eQE;bQB1IFAo<3ò. ڝ f#su/)a#%Â%53<|Oҡ#cNV$({K} cNchGP5M_SM{@C$RN]-*̪%r|P d M^kPP%(\6fd `R# kLk VW koJ|WaUw?8 Zf^(%'Niu-Kkv[ I1ˈk`s^Dе=/MԵ?OuGh-.)n@,#d "ЃѸzuەQO6]ʤz^Aia,|4ssqW˞4GtQEQERZuQEQE3n֍~tUv冕*>ѹA@'8 D ,teivzT)~kfݝČ6ȪP$ '3 $F? i'h]tM76 c H7AI#3n)Jվ)|l4WV2 W6[y>SJ֫ +[?> |t!SԴ▊UN((^+S|NozoX߈l(nHYhktw8*/\3^)~wzNkxz^4-RY,-d{"i>`Sa6tl?ᆙ?X:IWPN:EWDoյƏH?S=ZpU^^1@1?4m\ߊ**=O^?|5j붋Ξ- 19kۯ:~+Ɵ4;~&멨ƑhmBѱsphch*K:|~Ϟ9}uI-5 M/kV-K-aIDHVpW%_k5_h|y4+F\ּQ-KO|eeP\lj1~3H|1Uxŷ=ݓ-mCBe8]Cnq&&#ʏȺCIF> t3Ś.ዶף-.[#FG a-]CNOL<9+ķ~5܂ -=6K^iRu6Ы(XJ_WrFDbO.h'=ׇ߆:hWC 6,s 2$3'3²yrnn XyG8U<&|L x|=n^u3 Z;IRE H@Fj|w?|&675Ai.$46f(GcI2dw yn;}7}ߋZƗ6P3Ze sw[(u:W|RKxƞ?4/TOxbQ'$zz7d~uF~ GYC,veHa"0+7?g #z{o ZrZZF@dqq @تy |Y? Zi,ׁ'+$r[v\q,.F@ <@DP>MP|1=&9%v/B,Sm~hjY|3};An|}Aӧ8jDsӡ|LHeEmሞxV͹v<<֘~+>.u;}-TN.nM]wJqW`6ƣh!z9{q㯈>+ouw 4 iime"v#޺(^(()~'xn+ѭuIlcܥF0Aֹ>K{]Ciiq%$P%Y` *OVǁ~ 7ᔶxcAM&HlE<^IpVM|gM̲sTQM==Oc^SA=h'[D om\(-";5uƓk(E:P^NX7fVi.:` l\/|j|;w"[?kR64RoqLڿ7$𼚼V_ <kH4ѽD{QO^9ޥk?znի:X0ER͙J Ur+?k##ᦥL+߈, 4{yi =e8LN Qස~ _|i̡l*jO-蕆_HT]ٷoqR3~Ŷ~ >|D9O_V؂^K ƑN62}j/?h/ ;Gm%xN[u*nr iެ!kAĭjm/;MyjH,vWIڲ.ajw:ޝo7إfa9=_F~E.FqhUN((EQE埴o[σ 5m-GWhe -ާu XeC19Wi ~>~%Xu6fjWNDg{B! IcxWfwK |Wƒ?\Hl[q*M۩fq!έg#ŚNa[iϩ%^xW1F\I:, ș ,Gwq`IWzt\f8^>,|𖇡[ e(87Wz?5nC D|1a vI$)3K}?gMH^ޭyW+agya<)ݣ#P"P8%~ xkƚ7W GadsyKi|}|^Ԣ?16sojы0T8dHԝQ-Z~9xFxgXN]Iyuqݷsm'hr0-kkL6iB^`8ݜLQE*QEQEQLMdzxag1j1ԍѽôVlY}#eC<7J񵶫ew{2iie dN3L͎qRƓ"xg^.)aC?); 񥕫XV ,dH;D]tj?<[/j]cH:L6r@4o;mZ<3DYძDWaw_Q|7u=w^.:ek[k+c~3lpheFo"r`m!N¶x?q^53w*Ex]Zk;uei"aRfgQ՚B^-{ssjp"mH4QTĭr1}E&_pn?Z)W:((eW><)i^`>hҾbs4b?׆u_jV> g3#vin+筓\# $jJ~x& M+˭wUG]*K ,^K{B2neg`0]>>=y%Ya}FͣkK9BO_A\~~6 .kjl{|g~KVcT\DcΠ}_{wMj=*I .ąf^z>"'mQNW??rW_d~ZK6hw!*Utϩeqh6.W |w-~$B {t7 T "a\o'υ"%VDUu&@!f#$%UŸ|  Z_~{kp[[9(a♋c@;M]sן0uocG⾏?ʑXv9~r|#'!1x6g0Ork00:e(yS{%]U}F 'cGqqD̞&#. N43`{RjzntAYu[Vl&ʢ0nV'^(()QEEr;W66/ maɄe(>a_-'oT|[x9?xvIٌ.T8fi N|Zio:gSN_cos{Xg#A  VEz߅S۝/zUƏ"_Xmke#̿<۞s%y[# ~[=O^>^]hBVKOgk;е SR2|Qm|m}~g}6-TIc/0֭ $Ox[LR;66ַvm-)Kv[7kҸHGiI|W>z]~4.W˺{ZuIu>2x;^x 7-m&,yv/eE< 3ïLsvcde˵<_T-StN> +`#z?k _J~xH|]6"[WVKneAM4ټA&wxJR^Al]41ewx~)pN'|1]g^ƹiڌW[,i%uCmK rnomQ2޳7|)kij~14]\ռA#K%.lB_\)ǃ~Ϛn^k|b֫[fyjڬ[--c0$~#CW O)-̎4붐>g1aV@ vok_[|T~ YRkxe{+i%ي OX`/מW & LYl4("(\\V&#(=E-RZuQEQE((kc:;? |K.>'d |Ok?n,@>1 zӇ~W\O:t ^#׃^#QiBW 7mèxlYJ+daUܓDUЏB -SᎯ| /t8/IrJ;Dyaa{tC.\`6&2fwcZray_Fdzn3[xW׷)]E 3r O:FbxdD]w-id+[}Pcgke>C>LsfחKT^;FO5bKqmW}f O]SWPD{ I$vnYeEȋc|s8l~: ΅ymJP[ .Ȼ}6 *,v)2QiL i6sHPKNt+1i3LDrU{}E*QEQEQL>Aa $mھeyq0 ]\@򕝢*F*~%Z/MARwi2"|;kwZ} v-Ϙ>kpϬ|O{rHcDkhg(qO,_Ѽn45o^#[kn.-\t}т NCAxÚ ux{Ŧ:4ݻIhtA\* s#*|)*#wf G :j9׵;kk. ykxxU%EmwO7*MІ16 uT Vrj;R23)W:((e|Gf >j7i{NXg3Ė"@׍;G~_> @T66 5KxbvbϨq +Y$FFgŏu+q^m3EnHk">|nm4N?>5%_:|bVV⾓ú/$/|+=ZuMOfLWU5Oş|3qM;G!geqo<5H1*ƫP g|'5|WtxKqil6mRG-*6'L" YZ.t x{PӼ!B6~ç<ndfʼn,yҾ?{6m[]s·;cG} cGS^m cRonUi}=̈́6Aw3*&s?|[*xÚ|I- C(d]S•py2FFGj>!jYk-,h[=#8ޙQo MRHe&tvEUՔAUcլfn4-R+U3E"#&rB&7;N-RZuQEQEʮ#a ~\z>^OZiG\?x9Xiψ Sҿ1{h){M"1]F0Nu>?+gRoi; RE?L(쯠|rCKG=CP/9 b!X*X|׉g-S1'O-)5$iqGԖW61{O%w XAEsW:'Cpɠi!Mmn;Ih1B2Y0kY <$QҭA%ۗtŌ|ǂgP%Q_3_ #մ9w O;4ױü5θ;nko-m?%Ҽ1yZxkG #i[xF\~0|3Ix6k~$MhVEi [t~3Wx7׀5τ \:t{Gn9FNG]\o޾L.|L}Kssj6i.{%H"&( {VP d_ o>)V^2ՠ.gԦCH6.̐+ژ (!<qoc #Fڵ;P|).4-'[OANjVmqLYA>>!_e"K[?j:w.GM ÅbeɑH@Uh|s|N7;_~,<3gG{|j<%T3!ܡZ27Wro[y^#KHt =3JZ>fKe;{cAy'#HսE|e>xo_|%F" x?Jgk~5 YO} Hym̌gB q֕n_SoIFñ&sZ!Ҩ~:fiŧ^`?>/G=b]Ox| mg~d[_Kuuh(^(()QE'c{?<+JLzl~SK_pA5wï4xH_!4[X%V6ndgr׾kⶣG◍9m+űZ_G񾌰^A([&8^D[uY|]S_]B$Zv >팞s[̏u+b & s55#+RmqEsZ zYlu1G0-]鿳F :u=CQQ}7MujIK%&gإn/O&Ƴ7n<+ j o;Wjʢy! Ɓ`$|]A?2ffG־ O $g#;V5=[_1VҜ{;r-O/#/lKox&Z'ciRZȣ|__=KmHƐdw_׺EQJiQEQES(@5[>  Bn/;2!s,A7; ?]ɬ]iL±iP:PC#i/cغ7|]iZ*FR!K}svXA /O>uan ā{3Hݏ:.-tԭx]K00 Gz⬿f5Un;J&murobf$_.%B6XUO nnkO|;uK?1,VSL,*]A34zGោTPLłE k䑕_~:|"EνCFjK]_/4IiYr(QsJGްb?j~x_UìC b!u6cx4{H-B@dGs>C96.Ajۣ?=x~ ^% F-"[I#;UpnCm?λ鿶7j:Z|KhWϾ ߍ>?s~) &Aۉ{ַwag%|\}Ci1}n,ZXλLlv1$R{p2XWƺ'*jyey6r+At4QE֝EQEQE2(i?o7Dyc]cZ7 g:IM]g?˃Oi \K&EaX6ODZҼ3^!#]մ{,1 9V!&$ Ur@سm G5x,,7@arXI<\,Y[!'WO hzn_ Am--%FXUJoJLƿ>Ax%I6qkNi[C pfЀPJ )߃C .Ě-_a1yڊ(+ƀ(/şZi0?Nt|=oZ,o p]pr~'ZSǁiSxg5<=lu= iżhi^k>dHLASdqU cWDڧxVԆFlV&gQ$*]LQ5˺ kĿuzq7N?MlmoQgk2 %rޠAZ'>"<~w>$VͨèZG$mX bxcnEj?ړSG4W"5]%?Im@5byH֐Կ`h)'^2ĚVc (HmUh"PHE[x>RWq`_ZQERZuQEQE(/x^"äi:8PDs_r:Ьw<k9*c5Yon_X|i}h26ZNd937|ٳ#I%'陋^_yp;՟Gxq|#7iiO}qz:71Ao=ydV;|@ĕ|QStʃ4-?'?Jui˪O5լ aa[Py_G/ PѾ4x3_2~ҼCj5Kˠq dFK J:bުL|6yO7ME~6o]iqSfsJkAw?S/uIx†-mn3=זWp_)W:((eQ\c!𶪳/]4˱n$0G&޿;h/4 jZ:RkvUn ,G?_+kvOk.i]iVxR\([iadecHK)BoFjxmƅD+U#N&"^EmuefagR9ul?Ş95KFd${tv$HPp8EwiZrAGt8#ijCMѠy m!;A*$7]sό|<;xX6jwa#Xcu7MĶNKP8yk@!𭎙k$yzejBGš > t}9A6f5qkBb`a4QE֝EQEQE2((Gw}:ۯҼ}kVu9\hècNJ\ia GdDk&j='Iд-3L8 6"H (0k߀E~,D,v /z5Əkc?_ MmWli~[{]TokHm Oz b<_$rozȥpd]^%axxM~^_^/:IsI}VuX:"T@VڛY߇%GE`BҼ9WM;8qqX#%1p!ɓ 6I'ׇ5~ M(:oDU n~γGFB:[2XIZͬC?O~$Vk]hz8<+Xj"OyӴѺkWvk6eudUC賶$Lbթ4 4?k:߁񿇼A{Q~>|񲑟L-}]>eWőy[,- ɲWmŬfXmT]GF#sR 89QERZuQEQE2 y<yiTK=uO ϊʞeCl!C>!;'DWjvwhrxꎶ Yv@n}'^>|y~"V֚ZVsZKpgٙbd$Xj-\xsd}i-5FO#=kȵm~~ѿgƹ1 1ԏf\P/Ö]]ۮcѴ8AYȸu|E G^|7h:t> Nc";I'S`^Q_9WU8t$VInfx=W*4?Vw>׺ŔNA{ۚ _xzTlux]u"qy Y\ϊ"?xmF~" >_?,Z{sq69qG⦣rAKz:ڭ֝p// srϗk'S< g7w6z[gE[$&k,˻*EH\@I^<}BY[6+]bG"WC"Pr|iEh7u~]6t6bD%[ ZhR 4(()j |E|=1[xS4;&0-"E-e 'yT.X`s{_Ƈ࿱j"]cTE y~-(?{ƭ hæꟶ͆wac+X}ůAӠhH4?.O wu7;FZռ3aL ӭNhk%JIioJ$ V7&Ҿ#xetO hV ]M=Y\0YDSˣ9* +_o4H |K> jyfko@L+daY { 5[\O N`fr܃Qީwg*#MЃ1,m۟>|>$/̾B5e?'᾿;~2]?<" NƗΒ9Xk|OFKfVqe?'OI6vw_mmQ|"yԜ>' iFq~5p(xDNuY //K3*.\*KW~%?ě爖B6V*k)Q\ykraYl3 ny/!F|I{_Z}gN\wCyo|+ݸ A qaKaYyQp6TH56 rx}ϽKEQEQE2hϿNQE|O_CῈ߳ )HB/t_ ]I־xY)[^#HquIX>VoJbWkr:W,PpMLe6>֟u;O/_^)eTr]ǹ@z+o|LW=bM-) mwmk'Vn)#ׂ~ 9`pڛM4q}k#֊+׀ :6f[?R+L]ćp`P 1 _?= >+5%ko=v֖#3P1m#Z?ٴ{{&]6Vlh Ƀf`/`=Ǣ|@u丗Oү.h́QCfdW u9@oiJm$cjJ(()QEQE핣\_uto>NQ=~6w^N5PI< `PJ0 D/ o?Iɸ=ji})\#~"9՟'Ak|s? . Et.M, _ `M~M>iahx6:o5b9%,Qݰ$G*/Wè꿵 *cg .ǓdiOR5QEQFhzӨ((QEQEW8u|Q‰&U IؾG-|Y][KԣΧ[-"A 6S&FUՀ!#Z? )1 n,nd Ǘs76N@T|6]C߸){x^Rwo߈ѱC!#5n9^koٓ:t}'S_n(M3My# V+/B<֖uvh{06 utڥH{QEQE֝EQEQE2((tFo8^Qўu$VqvF?޷JkYI Z}5(e a3 {ׇ|!m߶w3t qlo[mN⟀|`HFh; >bP+{߱iϩ|MuX̘ nN{Y-v1(C>v[I((UN((EQEQ^ @gKI-_-g?u𮢟^kh(:W|3H-l?!yt ;g:zVwǝZHjًKܾEƫ::ǰpkÿc]YuP!B?ߒ!ĺ+duʕ 4?kt]Z*a_^:3WEQEQJiQEQES($@n{ng#)hoy+x<[ys^HU`=\&0 둟b?M{OJ_w?h~: xZ2aIltk?*(i/ٟYPok6-Z}<ϽxW5ɥ~ VVfH]A7.F:vN| mc;z((zӨ((Q^Q|^MxH, AYnR;˗A##)z35~t *׬rϧ Lmo rOۿJԴ <'^Pc.VUb+#|c_ <{cS'4gmP^bAW̬C)V*x ]mW߶ůox,m +A*Ki:qʋm* ~#W >bC?Mv-ŵ9~dq^pxk$ٶ?L-#?yx+Hij򭥮}2FDi4&~źց/|<7 [O> v:Wq9 pWJ(()W:((e|#Sx[$^4ԭt;K9GraY 2.6x׃lOپ|)j6:ě5VHkb9oaĮ<w+൜KXӼCZx~Y,4({[bGU`m3PP:' ]2;[;x-R E 8$(% >$~<<-ZA;YC-Md}+ʿjoO-EF^p7*F)o38ȯa+\][q%gx`g6 &"=jyi|M,A |j֡{ ĞףO0\ <G0PHO ̚W}>X>0J‹v#Arfq_DYYim Ak,QCQ`V(((^(()U .Q0}m(J"d3y5?ݦkq6wI[2]AoJ09 pگ7WqKϼZ#eA?'"$P:*mY(xђ/qj.ψyQ BY+ Yq\^#V;3ySO$&|C^EQEQEQFEdQFEdQM(+޼{Ux+P>xJfk ^x{Rc泑ۖO kVFu/ BեBĒIar˽FIDe,Kp=\Rx R?4 6G Ղ>zAwi#S<0 _?'f{w9k܏ZO?eoFmՀ,p7}]1\gCj5Z6Ošd9>b;DnkcjV5m7þLJY) :ݯu()GZ\Q1F(bQ1F(6(EW5h??qJWf!ɃXȧ !WFVG?8P%D&"TB0ԐI }߇83A5eXc22)#:Px|3?a ݦ[/.#&{E|@$#DlO?j>OxRuQFQFO</z 7}k[練ݦ%"0j F+9|??!G2 V#ImeV't!!LqZ!/ZΙቼM[xGƺҥ(7v%p^5Kvi0ޥ8$QEQJ:Ө(()QM@lqzSnG'}DH>e`6em5ѢOwhsxZc"&6,l!%n.c `?Ɵ7YkzrCFv&$˴;BZwk~%#]lnmf[9k$3OP@#x6oM;R2?DĦPZ#,J]ՌLG$|j+#^]^ki7nlY0!ppzW'L> ՜g ]ij $07s$+]Q?𽗅4~kZ?>'t𾃦 䩞q-!$Wm]K)/^5xZ}co|ĩqhTEקQEQJ:Ө(()QEQEFW## _1kƗ{u6A=m|mG |-][lWf@xJ> ,5[=j7-#r&(~xS<_|9߂wF ͹4 l]QER(((eQEQ@ 4R@E `=z{upzR#րAs=Z(Q֝EQEQEQL(3jQ4MhYlV3>߷>ٯ!}AK?zi _h:&V+Myi/&u2HKmFuxFǼ5~a@w(%zψ!|exb1ŤZci" t+hQpwc+ +6~Սi%瀴.sc`EEDzT\)c,q}A b\tOڗQ"GMK+÷8f{cƑfI Rq~/Q9> kƥj:g- #_.k5wFНo~%1Z\𖇤 Y4,^HI+ZmT")b1!aF?4:/znZvm}Mm9 !VO+×&;9t]Pn5w(ՀcV\!hkSs6͟yIc[BX*;6;wS5U k%aKI$WT|_^lfVl^s>ٺM6׎Ժ ZgϡJs-m9]C\qt^-H/VwPه*A ot~{Zd?Jx.ng`dq =}~ګ6x4yzmwm!,YgԾL+sjftI>gQVٱ乧nm*X[DL37dc+ttmLn>ߤsqR}N;wܱm>n|fU 1ֵQywFimOsc-J xLL&agzs0}ۉױ@ %i=\6v%RLphƗh8DՖ~%ә 4E Md^\q ЗXn8C^@`{}z_ыqoX<趯/~GXo.ssm;j-y}69zcOoU <>_KDj$G O=MAUc)v7z^nwG6^z CCq̭<v6xLI6>Cf~+geivnOv)' H8EQTcAMnje{ѬQ3GM3Zt #Uke:%̖ۢoA2edwӿw=ӮybT<[7ϣg,KN.yi .nu{?ܯ1̾Z\% ϊ67ݩ#+>./C}2z^KZӬxYIAC+)ၕ͑?rj˰1:A?;Qh n9cCMq"a'cJTqHYpT]652OuWZ6gUhx.$Y}TI%)3 I%521m{!|ǻs$쮚6w;"4c8b{x#.2AC+i=Ev)1` dNpXNH.RI$I$TI%)$IJI$RI$I%)$IJI$S8BIM XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km&File written by Adobe Photoshop 5.0Adobed@      ^,  s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjzm!1AQa"q2#BRbr3$4CS%cs5DT &6E'dtU7()󄔤euFVfvGWgw8HXhx9IYiy*:JZjz ?v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*JvūƂm/~;d)w5~{a'ȖBʩEfOP'%':}x^HC)nVœWb]v*UثWb_v*UثWb]v*UثWb]v*UثWbr_U/՜Qz/Q3"їUtQEy Rѹ+&/ǤvnԌ^!o'Akxڭ,_'?lvU vџV)s ~IIU߃6eGKr f= GyZXl"UgVv8|LQ^ nY0Z%uMSZ[*)_L-2&^lKH,.rW²rK_󟟼0~^^@ #~`qq|ع?*iSp:3YK^Nb]v*UثWbv*UثWb]v*UثWb]v*UتHVLDe&3Wz孼Dn#ܾ21(۫Qyʾ\wtѽxC?Y̒Lviv;yY']2GZTڧETͨNy A[MO>{mN5=ޅnD g?-qg[.Z]i[#J#pf)IM}FI[AѸ/Ç?RGu[]GOK#? W rŪydy+3Z=70Old=kx2ae Hu|æsKad{Ye'F^'~{ f:cO \GzOEzިXq\NKǏ鐜c>JX ^kv\L U5YKOGQv*UثWb]v*UثWb]v*UثWb]XJSLm=%wf7ÒL2#1yMC5V1zYe@6eCI):ݩ+Ϳ>tnR6/* J#r7@|A;Snw2ExnщfN`[l饛&S3?05{mZ8arq/9^]Txx`ӛZR0Z.*%μb^@ 0(4ⶅMDޯ1nGZ^.tԒT% 2F.1')^^5;[4wibKU_S"ym?2jߢaia ĩ;|M~ߓ8ד5 Wͺm44^i7bVd1˂Ql#1 U궱X:rCs|t)3_- E2&i_mMoX'&؃ato4 :] NwK|31q'ZJek.Q=D A n]*f#azvG71i~Ps%)*qQT"wz|A݊v*UثWbv*UثWb]v*UثWbT]q&1a)Gsڪ$fF$ A^䜾8%'_#yz]UQ֧ᥣ.:͆.Uϙ<$R3=Fd䊿QaNNZ!sbQEBґGpdZoΑmn.un9=TKOGuo0zVzݶuaxzWe}uMI-mn>4~Y+ŬMk_0ۻ<\UFl>m}fW^Ӭ4 ~x,J퐔#BFOC|ɩkh:Ήm/:ihc'W$CZԣtX~^Vv_wT2qq2 c N-3wϮ;%Ks&/'*7/ԵKYmgJ_ DE!EC\ܵ/,⍛F"vF݊v*UثWbv*UثWb]v*UثT|_ A.>Kmb.fjɘA(&uK;UWHUD*y^m65Ǟ9!L'e&w5{2)-_=̍rGbfFFS9EsN*Y#R9J1j˓ߝ#.c4Uo/U2?yأ󖟔zKԏ 9{IuoU/?=$j/f9Iuyom _o|G3$Կ''nTЅDK/`tx_(?*:yKDYu~o2ʩ/3C'[#>3hI}a~yWju w~ '~b3qv]7I12./Ǹ6zhM͞N. <0y~Wp._⿷P g68\gMuY՝VytDki+lWej Og>>+6CQ9}1naLE`as8izI?'/F8p&[cX%M9 3*Ra4N>Շ7P>&KǷ1`v??sjJ,hÐ):^E6G\Vd^r_𹉖y,:(eIy{>y;7!(1u2&Ey.-6,!ENjr1 9ViEҥoLco9Q┛$bKqB挟SE*j7:%_D%Hbf},rc{~[z`/.Ou#UlMŖ br vkx ]IB/#Lia4 {_H.}bI%EflCK}kwoynѿk914jv[@WcOk ?s??:CcXF-F˗ğ:߲iV>—)5NQ}X_8^)W]fZ6M6ia=>~~^[\භW4O?oQ?/s?Of{mC_udz}6(_hLNUWoIs}6H&93@#t еiQbwan;[G#k4$}<ߨoae=BYw~9MęѵRk>=&Gh{GYo2M\_so )v|8paHHlja_ꐽƝcq|sy#wOɯ8?D_}̟c%s_輣-s5=j;yr ]?W)2}U.TuΛIL#|]IxZ^mm} ~?%o,qJ-:HQ|SSH;KGo949R5ky˺M{s;Rd'g}е)h/^Bs'BbI+w50y/[]6SƟT~YV~#'C/qUӴ?)Qoه4KY-"<=#>q?45+N[w%OjMpeR&'̺MwV-!HO6期haώQPG\GgM-o *YQNhk9`\Uثk#9=}τ<<ͥ[ֶ:z2c`tsprUvsi;O6iKɾ/[݃9h;Cj)p-KNkz=:Zuc{n)W2D\2w񐐰yogSev_חO-`ypdb-ZDoT/xjq*|>iz =YP|y2G3td3~^P/OרxR_+$f,sKڿnFX[%_?Z_e Oh?._AG~?KC6F[9<7'u/[yI&Zޅ#h߫B\Rco+x\O=5V q{xb㓖SF?&h_;ݹy[Z&.mp+Ntg80y_ ^ZSk70]g2F/Gg{ߌ^|^~uӗ>pO~Sy{C>PKmu"Ez Eki\SOܤPŸG4̿.^Y'<&‰qq 5ad>,b4ZOW_Z<7!{ :Ns|^9hqceN11Y>]4: Nv])yjeKa8d/?1~UjwvzӤȿ5?eԎAV]׵^(>-Ohh+?C/(x5p>Q%[o>_k7g4f+d*OٿSt2gM9v^?r7%1#,ej{}?w0Yx{?cy"OZ@9td1K fۡ~s[r͗w^p !~Kej߳LqK/?#O;kGyuϲ6srZ_\Rzw:]X]DUu|VSl?8lm㵵?ї0eQ'4XYU]\ {hd\\5/2k[=?Qnpà}R!/5+k;^eOwU%3S_"Ǐ?/ɋ{Ut Q ^?_3(NO<+i0iѿ57CP~^0?ao?cez`5\_󆿔o&ߺ :~נ7Տܟy}m^Os\!P ş4~SiyEW"WZW(K}$;=$%\2_/毕56.M,~X%Goc(2_$|ݩiX j7,_χ|n.B2t9t`}12_>`{&gyrwvGyX:$pD6>E,n뎈pN?J|3 WJѮn<{km>}Nݮ.║wN8eJ91OHy;;N-f6^`O/,p?.٭y_r4xe3q?ߔ^c#VOcIp2hrcrCTIx^ٹ^0O 2oD_!ǵo-zk0mԙ=/ZvV@&i}6}#יu5Y.o?{5VkK,rl#Gy~[{M.k?1z:m:lɦ|P?|LJK3,6iQאja~s?Ǘ\RⓅ˄?8?[KeVDЀ9Xr~ mo<罳J?z8]>ԭ~thyߕ_d0EX=/ffMYyɻGᗛe?'TԦ+WBǶG ?,ߔ?!M.,hosq}NQ'g:hv BLXo)R9`u~1E|3yMGLնdp\Γurrrts'|t.[;'ӌMdv]?>.+506؆XKXLJ \[ItҬ}~~ohtr(2)c%欇4?dn_?yRH4f,wdWş /<)/uub/?(j;wGæܰ}Y6tWJ= ,K\y~.n-~tՙ?k]>a|L^89 .בz{k]HQ*KZsYy|Kq鑚ގ:F2_ߥYe{޵[O:-monXe-6m]?]F,.|އ|~p~W{I4*=mazq - j3S)xKӓ zpJn:ȿ5=>a~E7?b_k=>a|\T7#`Cq/o6?Va j%=;?̧QT^?^oV\SC,R럖,(03fӬK.\oWJw3t*3>6bUt_6k>yw]OUob_>Y-^YT~x{xH^ W~l~T~digt7o.(~*˿0!h%Jcocͯ/o/5rꇇE^|8Uee]i50GƞFWo4㷪[ό_͆|Aiez"L J&Rft4)82`>"ӵ0hi-Wе ~wO.* lUڥů7د%KI'_lȏy}e޽=7ugMKF-M򦟥[i5͇y_xEp돬[ɾ(9_?BCqck :C-`0_OTq}G?lHqG݆\'gY>[:Q;;{Xss!u+}oPt{m?&2\BO.襾Y|nxp\俚ޛ8kgʲq{_[?# §.oĿnU=4b-3^JY|(ft䞯X;9Kax]+*đ?rOcgz? }Z1/'91lϨvZ-/ ,#(ɘV!Їɋc_!>*8S:7?|U~~] R8=ND^n?!?GW8z Cu=;C|x.-}F'O[v*UثWb]E8.C% 4X[\+r͗}6[.N~1qoOrqo2l-9%{tX'&ecIǞ㚬Z Z擡~//Ybo휋?2G\=sckVߘo4ynRXnxU|$pqnA:ى0jpU^znhߗ~ŗܑL_#_a~&ī?[X"_zۄUB$sfaV ՅWVSOZ+8S'͑pIcy41LKD\}DM mKuk[_NmfOKX7N+c4Q՚T䞯Uq9LwQo MB?>:IR^kbxP-5k+y7o,iY[k^4ڒY rU~/[zvqyyyמ.vB|N̍#wyjy&dσi~\r8myHҼ_Toii ms|+)Mw?3J4nR["*pxj~`\8&noUZetM8K+ܢ\/gPC q"$ID}%VLғrv4v*UثWb]v*v*UثWb]&dITA֜zamYgyJ~le/,^`%/. _̹r~Nîu}Jqn!֓}f~ _\mTMHcluԷ\78Ě4iΖo59?E*'Ó>`lӼsa_[uUS|9!QئH6I}f[;'V_W64:g{GKN<}ᔚqc6}CGwt|KW(zEc x_S2.>$H}:H+7d̉\~%~ ~u{gW;gv\22 Fz&3qmx~ڷ)3rDmh3_V4ުn/,b,ּRhSGx7)sO{;yYsM.;4RzaS-g|j3%)=C3H%*`JNN,݊v*UثWb]v*Uv*UثWb]`q8{O'x㙇'#.C<31K Xzf2LNdJ|&2p# CgnnW6=o](eo8J2qrB$_?_ӭ[[m~>~fdg.'PƴwI펫6337t,~qj5c/}g.jHeW~1SLًh?!l=m7̐Wܶ~s\vkv;m[Gnm~oW_K9v5)7TsoΏ%得gr$N/pD#Itʍ*7, 2ɞL=mOe6&-aUW1hp]ydw ?ۇ28}rycE6(.U<7u VLK-pG༙cꜜ?@WGu%̾`4tkUǔ k#6,1tLs|KVAqmnaGmk35}RNh=M"d)0,B/Y}URi[yy<.?k,9$@'yQ~YK: x|4`uX^;.螯+LrOW#}/̻9X[ӯ,No}rhHs3c˜l;{m_~XXh +WvVN4ˋvr XԥH~Xns[e9mχAYig.\hZ7f-mOrʜ~/-ɳ]Y'iD/gh`QnոLʎ2v^aڦo쮴g+G<ח<φ|R$d^~c麕t _JB߅JQ/M1H󊴞cyzA'?9H }5퍇l]‘s[Gf<ǚ^N5ˍCPKˋ!Ip˴c,f˫t_)+iѢ'8B&ič^Ӕ K,(`c=?aKS);\] ot`7Uc9* lTث\Wov*UثWb]v*UثWb]v*v*UثWb]v*UثU#eAe-w2,%ܰY+zjn˒ ://0h:de":|}}>7b]v*UثWb]v*UثWb]v*UثWv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*Uv*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*U;( %D/ 0|DTimesNew RomanTT0>ܖ 0ܖDVerdanaw RomanTT0>ܖ 0ܖ" DArialaw RomanTT0>ܖ 0ܖ"0DWingdingsRomanTT0>ܖ 0ܖ@DTimes New RomanTT0>ܖ 0ܖ@ .  @n?" dd@  @@`` |`  |o #$%&'(+2 89<=>?@ A DEFGH/XR$DNgϔ@ݱsmR$yn~eqam 0AA 3333ff@38#$ ?O ʚ;[8ʚ;g4gdgdy 0Rdppp@ <4!d!d w 0T ><4dddd w 0T > <4BdBd x 0TT ___PPTMac11@f   hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography    hnamd` Arial&Monotype Typography  0namd(Verdana h___PPT2001D<4X |___PPT10\ ppD,___PPT9f80n&WvlHMU+vnPNG  IHDR asRGB`PLTEkjjkjjUUTU@@@??@++*+**M#A cmPPJCmp07128I tRNS@f>IDAT1W}{{J %s4!u61QJuRW&x&vxIENDB`/ 0 DV\ 6? %O =&= A new antivirulence approach against pathogenic bacteria 4>9(May 2005 Sonia Escaich - President & CSO,)(  Corporate overview Biopharmaceutical company specialized in antibacterial drug discovery for prevention of severe infections especially nosocomial Portfolio of intellectual property Virulence validated targets  Preclinical development of inhibitors small molecules Experienced management and R&D team - Prestigious academic partnerships - 3 R&D grants (ANVAR, Genhomme, BioSecurity) 20 Employees: 1 CEO/CSO, 1 director MedChem, 9 biologists/biochemists, 7 medicinal chemists (8 Ph.D,10 RAs) 2 G&As Incorporated mid-2001 - Located at Biocitech Parc, Paris (France) EUR 10.2M (USD 13M) raised since 2002 - Investors: BioAm, Axa PE, Auriga, Credit Agricole PE.PSPPfPPre dr "  C   8<MUTABILIS research objectives   Discovery of innovative anti-virulence treatments for nosocomial infections Therapeutic molecules : Inhibition of virulence factors. Therapeutic vaccines and antibodies N`3`3: !%   M:%  06      b  9Background: Medical need for new anti-infective therapies$:9 Nosocomial infections (NI) occur in 2-10% of hospitalized patients (ICU, Surgery, internal medicine& ) Three types of pathogens: Gram+ bacteria: 45%. Gram- bacteria: 35%. Others: 20%. Complications of nosocomial infections generate extensive hospitalization, and intensive care costs. Severe infections and sepsis can be lethal (30% cases) The increasing number of invasive procedures and the emergence of antibiotic resistance are causing a real public health problem Antibiotics-based treatments result in the destruction of commensal bacteria and drug resistance Newer antibiotics are kept as last resort therapy PgPPRP8PPoDg   >KPathogenic bacteria use a range of virulence factors to establish infectionLL L ?@MUTABILIS approach to virulence$!     Scientific strategy:   Drug approach: Selective inhibition of pathogenic bacteria by targeting virulence factors necessary for bacterial spreading in blood Virulence inhibitors do not perturb development of commensal bacteria Diminished risk of developing resistant mutants because of lower selective pressure This lead to the discovery of new classes of antibacterial molecules that are not classical antibiotics Vaccine approach: Inhibition of specific pathogens in a bacterial species Preventive vaccine/passive immunity for nosocomial infections6PxPvxPPhpPPPP9P>Py  wB    M> :@THERAPEUTIC APPROACH: Antibiotics versus virulence inhibitors AA$#    ,Common ground in both approaches: Infections are treated through eradication of bacteria in the blood. Advantages of virulence inhibitors: Virulence inhibitors do not perturb development of commensal bacteria. Diminished risk of developing resistant mutants because of lower selective pressure.#F(#E& - ;7Anti-virulence product profile opens preventive therapy88 8 Product profile: Anti-infective agent (not an antibiotic) which eradicates bacteria from the blood and leaves the commensal flora untouched. Product characteristics: No induction of bacterial resistance. No cross resistance with existing antibiotics. Large gram- spectrum. Large gram+ spectrum. Gram- and gram+ combination. Product positioning: Preventive therapy: compound will be used on its own. }6}4    V   {  K BVirulence inhibition: plan- $       Drug discovery$Objective: Discovery of new class of antibacterial molecules for selective inhibition of pathogenic bacteria Discovery process: Target identification (complete Tn mutagenesis of pathogenic Gram+ and Gram- pathogenic bacteria) and validation (KO mutants phenotype, protein function, consevation& ) Rational drug design, virtual screening, hit identification mZ0ZZZ0ZZ d  ,x B2@Anti-virulence product profile opens preventive therapy markets.A-A@   C UMUTABILIS targets: conserved, required for virulence and systemic infection but not for commensalism. MUTABILIS developed assays needed for pharmacological studies. Efficacy prediction through animal model: targets functions are conserved in animal species and man. MUTABILIS using rational approaches did identify inhibitors molecules. DU$Z%ZU&X       F Research area of interest:  Comparative genomics + physiopathology of infectious diseases Interactions bacteria/host Metabolic pathways common to pathogenic bacteria conserved targets Bacterial membranes and pharmacology : why some drugs get through or not? ?M  J " ?ML   /&'(+<@ADE   0` 33` Sf3f` 33g` f` www3PP` ZXdbmo` \ғ3y`Ӣ` 3f3ff` 3f3FKf` hk]wwwfܹ` ff>>\`Y{ff` R>&- {p_/̴` 33` 333f` 33` 33>?" dd@x?" dd@  " @ ` n?" dd@   @@``PR    @ ` ` p>>L0 0c(    6| #" `   _'Cliquez pour modifier le style du titre(( R  0, #" `z `  vCliquez pour modifier les styles du texte du masque Deuxime niveau Troisime niveau Quatrime niveau Cinquime niveau4w   0 "   L"0     0P "^ `  p*$0     C JA2E Coli mut 4 copier BLEU"gpx  <f3#"  `'YMH  0޽h ? =$33___PPT10i.(@<+D='  = @B + 1_Masque 1  0L0 @(    C JA2E Coli mut 4 copier BLEU"2   6َ  "C    _'Cliquez pour modifier le style du titre((   0ێ  " `     p8Cliquez pour modifier le style des sous-titres du masque99 H  0޽h ? =$33___PPT10i.(6+D='  = @B +> 0 PN(    0 P     X*   0̒      Z* d  c $ ?   :  0͒  @   vCliquez pour modifier les styles du texte du masque Deuxime niveau Troisime niveau Quatrime niveau Cinquime niveau4 w  6L  `P   X*   6  `    Z* H  0޽h ? 3380___PPT10.q 0(P(    00}x  P   x  `*     0̕    x  b*     6Hx  _P  x  `*     6̇x  _  x  b*   H  0޽h ? 3380___PPT10.:y 0 6.0(  x  c $P u    x  c $ 9      <;[ " H  0޽h ? 33y___PPT10Y+D='  = @B +  0 `V( f+   s * ?S"    r  S    H  0޽h ? 33y___PPT10Y+D='  = @B +'   0 > 6 4(  4 4  `dF38c8c?c"$`     4  @ 0e0e     ? @  5%3 8c1Ȝ     ?A)BCD|E||c " ?@  `    @ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `abN 5%  N 5%  N    5%    !"?N@ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `ab%  H 4 0޽h ? 33___PPT10i.20J+D='  = @B +  0 p( lY   s *H ?S" t     s *T0 ?S" z   H  0޽h ? 33y___PPT10Y+D='  = @B +   0  L  (  L L  N38c8c?S"      L fAsans titre37 ^2 L 6t  L 6Ƞ  gPathogenic bacteria$0 3   L BWS"`?s  gSpecific Immunity&0    L B3S"`?j s  eInnate Immunity&0 3  d"  L <0 ^"  L 6d"  L <_S F   L Bl  Z Colonization 0    d" L <*a6 c  L BT  VInvasion 0     L 6Le Vv  fShield to immune system0    L B %   TToxins0    L 6$ P  dVirulence mechanisms 0    L BT( C"?:  ] Host defenses 0   X L 0P@ f X L 0PJf ^" L 6SF F  L 0`- s C  dEnvironment adaptation0   H L 0޽h ? 33___PPT10i. +D='  = @B +&  0 =5 T(  T T  N6 38c8c?S" '   v T N!qAA sans titre3 IL  "+ T# @K<r T # Gq9IN "ia* T 3 9 C"?(+ fGut 20    T 3 > C"?1Y#iu% gBlood 00    T BB    dSystemic infection"0     T 0G P  ^Selective inhibition of the virulence factors required for systemic dissemination in the host.*_P _K_ _  H T 0޽h ? 33___PPT10i.3+D='  = @B +  0 VNl(  lx l c $O z `   . l  \0e0e 8c8c?s"*0e     H l 0޽h ? 3380___PPT10.9@AER  0L0 Db(  D D  0$[ 3?S" |R   x D c $4` $   H D 0޽h ? =$33___PPT10i.<hʋ+D='  = @B +  0L0 Hb(  H H  0 3?S"     x H c $8 $   H H 0޽h ? =$33___PPT10i.}@+D='  = @B +i  0 @d (  d d  6|f 3?S" ,   f  0 d 6c /7  6Mutagenesis of every coding sequence in the genome of a model bacteria. Identification of pathogen genes which are essential for producing systemic infection. Validation of these genes as therapeutic targets in experimental models of infection. Drug development based on molecules which inhibit these targets.:75X _KA$     '   TTH d 0޽h ? ̙33y___PPT10Y+D='  = @B +  0 (h( + ( ( s * ?S"     ( S !f zj    -/H ( 0޽h ? 33y___PPT10Y+D='  = @B +  0L0  z(  X  0mX  0mX  0mp   f 0e0e3 8c8c?"f0e`  ?    f  +  Tf 2?"6@ NNN?N TF  iHealthy individuals&0   6  Tf 32?"6@ NNN?N TF  tPatients at risk of infections&0   5   `t G#=HM2?"6@ NNN?NA  gInfected patients&0       <D͎  ?"6@ NNN?N// a VACCINATION& 0        <f  ?"6@ NNN?N// c ANTIVIRULENCE&0       <f  ?"6@`NNN?N/:/ a ANTIBIOTICS& 0       <f  ?"6@ NNN?N u!Specific to the risk of infection$"0 " "   H  ?"6@ NNN?N ! ?Haemophilus Meningococcus Pneumococcus E. Coli Streptococcus B 4@1 ?N           < x  ?"6@ NNN?N&F kBroad spectrum therapy $0     <x  ?"6@ NNN?Ns } Transplantees (kidney, bone marrow, liver, etc.) Intensive care patients Cancer patients undergoing treatment Kidney failure Corticoid treatment 61      <P x  ?"6@ NNN?NM sPathogenic strains Prevention $ 0    2  Nxx  ?"6@ NNN?N \  > 2  Nx  ?"6@ NNN?N*\  > 2  Nx  ?"6@ NNN?NW\  > H  0޽h ? 33g___PPT10i.2:|f+D='  = @B +  0 ` lJ(  l~ l s *x '7 x  :B l 3 :B l 3 :B l 3  :B l 3 hi:B l 3 7 p8 :B l 3 4 x@5 :B  l 3  p :B  l 3 C D :B  l 3 & ( :B  l 3 p  l B x  3?"` x" Conclusions: virulence projects &#   # H l 0޽h ? gggGGGy___PPT10Y+D='  = @B +n  0L0 tV(  t t s * 3?S"     r t S | z `   H t 0޽h ? =$3380___PPT10.C]p 0 xp@d(  dR d 3    v d # p  @   " H d 0޽h ? 3380___PPT10.q 0 ` (  X  C    x   S 9x  @  x  " H  0޽h ? 3380___PPT10.:Ø 0 p (  X  C    x   S -x  @  x  " H  0޽h ? 3380___PPT10.:Ø 0  (  X  C    x   S LDx  @  x  " H  0޽h ? 3380___PPT10.:Ø 0  (  X  C    x   S Dx  @  x  " H  0޽h ? 3380___PPT10.:Ø( 0 88(  8d 8 c $!   x  8 s * Zx  0  x  " H 8 0޽h ? 3380___PPT10.4( 0 P8(  Pd P c $!   x  P s *Tx  0  x  " H P 0޽h ? 3380___PPT10.*kq( 0 X8(  Xd X c $!   x  X s *ddx  0  x  " H X 0޽h ? 3380___PPT10.*kq 0 Ph8(  hd h c $!   x  h s *4jx  @  x  "  H h 0޽h ? ̙33( 0 pp8(  pd p c $!   x  p s * ex  0  x  " H p 0޽h ? 3380___PPT10.*kqrV KY f Ĭ#`;GRĮܰ+ 28\:0Ԃ$>ixTNHOh+'0?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgijklmnopqrstuvwxyz{|}~ Root EntrydO)PicturesCurrent UserSummaryInformation(lUPowerPoint Document(hDocumentSummaryInformation8Root EntrydO)@Ʀ^f @PicturesCurrent UserSummaryInformation(lU ՜.+,D՜.+, $ , 4< DLT\ d 3Affichage à l'écran,ɇ怀Ƀ뛼ˬ蘒뿿큠ʒ撐ɇ뛼뿿큐g  TimesVerdanaArial WingdingsTimes New Roman 1_Masque 1> A new antivirulence approach against pathogenic bacteria Corporate overview!MUTABILIS’ research objectives:Background: Medical need for new anti-infective therapiesLPathogenic bacteria use a range of virulence factors to establish infection#MUTABILIS’ approach to virulenceScientific strategy:ATHERAPEUTIC APPROACH: Antibiotics versus virulence inhibitors 8Anti-virulence product profile opens preventive therapyVirulence inhibition: planDrug discoveryAAnti-virulence product profile opens preventive therapy markets.Diapositive 13Research area of interest: Polices utiliséesModèle de conceptionTitres des diapositivesP <D_PID_LINKBASEAPowerPoint Document(hDocumentSummaryInformation8@